GCP
MRSN

GSA Capital Partners’s Mersana Therapeutics MRSN Stock Holding History

GSA Capital Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,867
Closed -$140K – 1932
2025
Q2 		$140K Buy
+18,867
New +$166K 0.01% 1580
2025
Q1 		– Sell
-20,332
Closed -$727K – 1926
2024
Q4 		$727K Buy
20,332
+9,461
+87% +$489K 0.05% 620
2024
Q3 		$514K Buy
10,871
+8,553
+369% +$377K 0.04% 885
2024
Q2 		$116K Buy
2,318
+908
+64% +$65.7K 0.01% 1519
2024
Q1 		$158K Buy
+1,410
New +$140K 0.01% 1439
2023
Q4 		– Sell
-4,072
Closed -$129K – 1762
2023
Q3 		$129K Sell
4,072
-11,432
-74% -$543K 0.01% 1365
2023
Q2 		$1.27M Buy
15,504
+7,325
+90% +$1.07M 0.13% 197
2023
Q1 		$840K Buy
8,179
+6,889
+534% +$967K 0.08% 410
2022
Q4 		$189K Sell
1,290
-5,390
-81% -$911K 0.02% 1200
2022
Q3 		$1.13M Sell
6,680
-70
-1% -$11.4K 0.15% 115
2022
Q2 		$780K Buy
6,750
+3,602
+114% +$339K 0.12% 244
2022
Q1 		$314K Sell
3,148
-335
-10% -$39.1K 0.04% 860
2021
Q4 		$542K Buy
+3,483
New +$678K 0.07% 542
2020
Q3 		– Sell
-362
Closed -$212K – 1336
2020
Q2 		$212K Buy
+362
New +$124K 0.12% 317

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GSA Capital Partners's MRSN Position: Q3 2025 in Review

GSA Capital Partners sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 18,867 shares — an estimated $140K sold.

GSA Capital Partners first reported a position in MRSN in Q2 2020 and held it in 14 quarters. The position peaked at $1.27M in Q2 2023. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • GSA Capital Partners reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 18,867 Mersana Therapeutics shares in Q3 2025, an estimated $140K.
  • GSA Capital Partners first reported a position in Mersana Therapeutics in Q2 2020 and held it in 14 quarters.
  • GSA Capital Partners's Mersana Therapeutics position peaked at $1.27M in Q2 2023.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.